A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 9, 2011, Pages 1569-1577

  Stinchcombe, Thomas E ^a   Peterman, Amy H ^b   Lee, Carrie B ^a   Moore, Dominic T ^c   Beaumont, Jennifer L ^d   Bradford, Daniel S ^e   Bakri, Kamal ^f   Taylor, Mark ^g   Crane, Jeffrey M ^h   Schwartz, Garry ⁱ   Hensing, Thomas A ^j   McElroy Jr , Edwin ^k   Niell, Harvey B ^l   Harper, Harry D ^m   Pal, Sridhar ⁿ   Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^c IL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e Highlands Oncology Group   (United States)

^f Cape Fear Valley Health System Cancer Center   (United States)

^g Savannah Hematology Oncology Associates   (United States)

^h Rex Hematology and Oncology   (United States)

ⁱ Carolinas Medical Center NorthEast   (United States)

^j NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^k Kingsport Hematology Oncology Associates   (United States)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m Northern New Jersey Cancer Associates   (United States)

ⁿ Carolinas Hematology Oncology Associates   (United States)

more..

Author keywords

Cumulative illness rating scale for geriatrics; Elderly; Quality of life; Targeted therapy

Indexed keywords

ERLOTINIB; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONTROLLED STUDY; CUMULATIVE ILLNESS RATING SCALE FOR GERIATRICS; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DYSPNEA; FATIGUE; FEMALE; GERIATRIC PATIENT; HEALTH STATUS; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; SYMPTOM; TREATMENT OUTCOME;

EID: 80052273497     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182210430     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
3. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544. (Pubitemid 46630948)
4. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: Experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-462. (Pubitemid 40994510)
5. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-6266.
6. Havlik RJ, Yancik R, Long S, et al. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994;74:2101-2106. (Pubitemid 24304381)
7. Pallis AG, Gridelli C, van Meerbeeck JP, et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-smallcell lung cancer in an elderly population. Ann Oncol 2010;21: 692-706.
8. Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: An analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007;25:5570-5577.
9. Jatoi A, Hillman S, Stella P, et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 2005;23:9113-9119.
10. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999;91:66-72.
11. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372. (Pubitemid 36395256)
12. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 2000;18:2529-2536. (Pubitemid 30432518)
13. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007; 25:760-766. (Pubitemid 350002874)
14. Simon GR, Extermann M, Chiappori A, et al. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall- cell lung cancer (NSCLC) who are 70 years of age or older. Cancer 2008;112:2021-2029. (Pubitemid 351574078)
15. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966. (Pubitemid 46972777)
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
17. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41:237-248.
18. Cella D, Tulsky D, Gray G. The functional assessment of cancer therapy scale: Development and validation of the general measure. J Clin Oncol 1993;11:570-579. (Pubitemid 23071057)
19. Cella D, Bonomi A, Lloyd S, et al. Reliability and validity of the of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-200.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
21. Cella D, Herbst RS, Lynch TJ, et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 2005;23:2946-2954. (Pubitemid 46224113)
22. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
23. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
24. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
25. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol 2009;27(suppl):abstract 8006.
26. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
27. Crino L, Cappuzzo F, Zatloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): A randomized, phase II study. J Clin Oncol 2008;26: 4253-4260.
28. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794. (Pubitemid 41103589)
29. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
30. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552. (Pubitemid 46733081)
31. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784. (Pubitemid 41103588)
32. Quoix EA, Oster J, Westeel V, et al. Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28:2.
33. Hensing TA, Peterman AH, Schell MJ, et al. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer 2003;98:779-788. (Pubitemid 36959275)